Adhesion formation is a major source of postoperative morbidity and mortality. In this study, the ability of a variety of lazaroid formulations [the antioxidant 21aminosteroid PNU74006F (tirilazad) and the non-steroidal 2-methylaminochroman derivative PNU83,836E] to reduce i.p. adhesion formation in three rabbit models was examined. In initial studies, PNU83836E was administered via Alzet miniosmotic pump to the site of injury. In the sidewall and double uterine horn models, PNU83,836E was administered via Alzet miniosmotic pump for the entire postoperative interval. In the sidewall model, there was a dose-dependent reduction in the area of the sidewall injury that was involved in adhesions. In the double uterine horn model, PNU83,836E was administered via Alzet miniosmotic pump to the area of injury for 1, 2, 3 or 7 days. Administration for as little as 24 h after surgery significantly reduced the extent of adhesion formation and the reduction was increased if it was administered for longer. Further studies were conducted in which various lazaroid formulations were administered as a bolus at the end of surgery. In both the sidewall and double uterine horn models, administration of either PNU83,386E (in citrate buffer) or PNU74006F (in cyclodextrin or lipid emulsion vehicles) at the end of surgery reduced adhesion formation. Administration of a bolus of PNU74006F 10 min prior to initiation of surgery with or without additional treatment at the end of surgery further increased its efficacy in the reduction of adhesion formation. Administration of a minimum of 1.5 mg before and after surgery (3 mg total) was required for maximal efficacy. These studies demonstrate that pre-and postoperative administration of either a steroidal (PNU74006F) or non-steroidal (PNU83,836E) lazaroid intraperitoneally reduced the formation and reformation of postoperative adhesions in three animal models.
Introduction
Adhesion formation is a major source of postoperative morbidity and mortality (Ellis, 1982; diZerega and Rodgers, 1992a ; Thornton and diZerega, 1996) . General and gynaecological surgical procedures are most frequently implicated in clinically significant adhesion formation. Intestinal obstruction is the most serious complication of i.p. adhesions (Menzies and Ellis, 1990; Menzies, 1992; Scott Coombes et al., 1993; Blanco, 1997; DeCherney and diZerega, 1997; Fredermann et al., 1997; Schoffel et al., 1997; Treutner et al., 1997) , most following hysterectomy (Ratcliff et al., 1983; Strickler et al., 1994) . Adhesions are associated with chronic or recurrent pelvic pain and secondary infertility in females (DeCherney and Mezer, 1984; Trimbos-Kemper et al., 1985; Howard, 1990; Stout et al., 1991; Duffy and diZerega, 1992; Peters et al., 1992; Bakkum and Peters, 1997; Lundorff, 1997; Marana et al., 1997) . Most recently, intra-operative complications, such as organ damage during laparoscopy due to misplacement or increased bleeding due to adhesiolysis, and prolonged operative time have been recognized as serious consequences arising from postoperative adhesion formation.
Various approaches for the prevention of adhesion formation have been actively explored (Adhesion Study Group, 1983; diZerega and Rodgers, 1992b; diZerega, 1994 diZerega, , 1996 diZerega, , 1997 Thornton et al., 1997) . It is well known that good surgical technique is important in reducing adhesion formation (Ordonez et al., 1997) . However, adjuncts to good techniques are also needed. Physical barriers have been used in an attempt to prevent adhesion formation by limiting tissue apposition during the critical period of peritoneal healing, thereby minimizing the development of fibrin matrix between tissue surfaces (diZerega, 1994; Treutner et al., 1995; Thornton, 1996) . Barrier agents which have been employed include: oxidized regenerated cellulose (Interceed; Ethicon, Somerville, NJ, USA); expanded polytetrafluorethylene (Preclude; WL Gore, Flagstaff, AZ, USA), hyaluronic acid combined with modified carboxymethyl cellulose (Seprafilm; Genzyme, Cambridge, MA, USA), iron cross linked hyaluronic acid (Intergel, Ethicon) and 32% dextran 70 (Hyskon; Pharmacia, Piscattaway, NJ, USA). For example, Interceed was recently shown to reduce ovarian adhesion after cystectomy or electrosurgical treatment for polycystic ovarian syndrome (Keckstein et al., 1996; Saravelos and Li, 1996) . Antiinflammatory drugs, including corticosteroids, antiinflammatory peptides, hirudin analogues and non-steroidal antiinflammatory drugs, have been evaluated experimentally for their ability to reduce adhesion formation, but formal clinical evaluation of these agents is needed (Rodgers et al., 1990 (Rodgers et al., , 1994 (Rodgers et al., , 1996 (Rodgers et al., , 1997 LeGrand et al., 1995) . A third approach involves the removal of fibrin deposits through fibrinolytic enzymes, including tissue plasminogen activator (tPA) as reviewed in (diZerega and Rodgers, 1992b) .
In the present study, various formulations of lazaroids, including a non-steroidal (PNU83,836E) and a steroidal (PNU74006F) lazaroid, were tested for their ability to reduce adhesion formations when administered to the site of injury. Lazaroids are a unique group of 21-aminosteroids (steroidal) and 2-methylaminochroman (non-steroidal) compounds which exert a protective effect against tissue damage and/or ischaemia (Hall, 1992; Thomas et al., 1993) . In several models of traumatic and ischaemic injury to the central nervous system, lazaroids have been shown to prevent secondary tissue injury associated with oxidative cell damage (Hall, 1992) . The protective effects of lazaroids have been attributed to their ability to inhibit lipid peroxidation reactions as well as to reduce the production of reactive oxygen metabolites by leukocytes and monocytes (Braughler et al., 1987; Fisher et al., 1990 Fisher et al., , 1991 Kalra et al., 1994; Shappell et al., 1994; McCall, 1995) . Based upon their ability to reduce tissue damage secondary to traumatic ischaemic injury, the effect of various lazaroid formulations on the formation of adhesions was examined in three animal models.
Materials and methods
The surgical procedures were conducted with the approval of the University of Southern California Institutional Animal Care and Use Committee. All animals tolerated the procedure well.
Animals
Female New Zealand White rabbits, 2.4-2.7 kg, were purchased from Irish Farms (Norco, CA, USA) and quarantined in the University Vivaria for at least 2 days prior to use. The rabbits were housed on a 12:12 light:dark cycle with food and water available ad libitum.
Materials
The steroidal lazaroid (PNU74006F in various formulations described below) and non-steroidal lazaroid (PNU83,836E; 0.06-0.6 mg/ml in 0.02 M citric acid, 0.0032 M sodium citrate, 0.077 M sodium chloride, pH 3.5) were a gift from Pharmacia UpJohn (Dr John McCall, Kalamazoo, MI, USA). The Alzet miniosmotic pumps were purchased from Alza Corporation (Palo Alto, CA, USA). Polyethylene (PE-50) tubing from Clay Adams was used for the delivery of the drug from the s.c. space to the site of injury. The sutures used were as follows: 4-0 Ethilon (Ethicon, Raritan, NJ, USA) was used to place the pump and tubing and 3-0 coated Dexon II suture (Davis and Geck, Manati, PA, USA) was used to close the peritoneum and skin.
Surgical models
Sidewall model This model of adhesion formation has been described in detail elsewhere (Rodgers et al., 1996 (Rodgers et al., , 1997 . In brief, rabbits were anaesthetized with a mixture of 55 mg/kg ketamine hydrochloride and 5 mg/kg xylazine i.m. Following preparation for sterile surgery, a midline laparotomy was performed. A 3 cmϫ5 cm area of peritoneum and transversus abdominus muscle was removed on the right lateral abdominal wall. The caecum and bowel were exteriorized and digital pressure was exerted to create subserosal haemorrhages over all surfaces. The damaged intestine was then lightly abraded with 4 in.ϫ4 in., 4-ply sterile gauze until punctate bleeding was observed. The caecum and bowel were then returned to their normal anatomical positions. The medication was delivered via Alzet miniosmotic pump as described below. The rabbits received i.m. morphine 2444 or bupronex for analgesia postoperatively. After 7 days, the rabbits were killed and the percentage of the area of the sidewall injury that was involved in adhesions was determined by two blinded and independent observers. In addition, the tenacity of the adhesions was scored using the following system: 0 ϭ no adhesions; 1 ϭ mild, easily dissectable adhesions; 2 ϭ moderate adhesions; nondissectable, does not tear the organ; 3 ϭ dense adhesions, nondissectable, tears organ when removed. A reduction in either the area or the tenacity of the adhesions was considered to be beneficial.
Reformation model
Animals underwent an initial surgery comparable to that described above under Sidewall Model. One week after this initial surgery, the rabbits underwent a second laparotomy and existing adhesions were lysed. One week later adhesion reformation was assessed by the above scoring system.
Double uterine horn model
This model was previously shown to lead to severe adhesion formation after surgery (Nishimura et al., 1984; Rodgers et al., 1996 Rodgers et al., , 1997 Rodgers et al., , 1998 . The rabbits were anaesthetized (130 mg/kg ketamine and 20 mg/kg acetylpromazine given i.m.) and prepared for sterile surgery. A midline laparotomy was performed and both uterine horns were traumatized by abrasion of the serosal surface with gauze until punctate bleeding developed. Ischaemia of both uterine horns was induced by removal of the collateral blood supply. The remaining blood supply to the uterine horns was via the ascending branch of the utero-vaginal arterial supply to the myometrium. After injury, the miniosmotic pump was placed to deliver the medication and the abdominal wall was closed in two layers. The rabbits received i.m. morphine or bupronex analgesia postoperatively. After 7 days, the rabbits were killed and the degree of adhesion formation was determined. In this model, an initial score to represent the overall extent of adhesions was given (scoring system used was consistent with Rodgers et al., 1990) . The percentage of the surface of the horn involved in adhesions to various organs (including bowel, bladder, the horn itself and the contralateral horn) was also noted and is detailed in the Results section.
Administration of PNU83,836E to injury site via Alzet pump
In order to deliver the compound to the site of injury, a tube was attached to a miniosmotic pump (Model 2ML1) that was placed in a s.c. pocket adjacent to the midline incision. The pump delivered material at a rate of 10 µl/h for 7 days. The tube was run from the attachment site to the pump in the s.c. space to the site of injury (sidewall excision or between the bladder and the uterine horns). The tube was attached to the sidewall with 4-0 Ethilon suture to immobilize it to the desired delivery site. The pumps placed in the control rabbits contained vehicle (citrate buffer: 0.02 M citric acid, 0.0032 M sodium citrate, 0.077 M sodium chloride, pH 3.5) only.
Bolus administration of lazaroid
The following formulations of PNG74006F were tested by administration as a bolus: Freedox IV (25 mg/ml PNU74006F in a proprietary cosolvent system, diluted to 1 or 5 mg/ml with lactated Ringer's solution or 0.01 to 10 mg/ml in saline in dose-response study), PNU74006F in cyclodextrin (10 mg/ml, diluted to 1 mg/ml) or PNU74006F in lipid emulsion (11.8 mg/ml, diluted to 1 mg/ml).
In an initial study, PNU83,836E, 1 mg/ml in citrate buffer, was administered at the end of surgery in a volume of 5 ml. In this same study, PNU74006F, formulated in cyclodextrin or lipid emulsion, was also evaluated in a volume of 5 ml.
In a second study, the Freedox IV formulation was tested at two concentrations (1 or 5 mg/ml). The drug was administered in a volume of 5 ml either 10 min before the initiation of surgery (i.p. injection pre-treatment only) or 10 min before and at the end of surgery (pre/post-treatment groups). In this study, dilutions were made using lactated Ringer's solution on the day of surgery.
In the dose-response and reformation studies, the Freedox IV was diluted in saline. An equal mass of medicament was given at the beginning (in 2.5 ml total volume) and end of surgery. The volume of treatment was 2.5 ml at the initiation of surgery and 15 ml at the conclusion of surgery, the concentration being varied to keep the mass constant. The total mass of drug given per rabbit is presented in the graphs.
Statistics
Six or seven rabbits were tested at each dose and time point. For the sidewall model, the possible differences between the groups were analysed by the Student's t-test. In the double uterine horn model, the difference between the test groups was determined by analysis of variance on the ranks. The extent scores for adhesions between individual organs in the double uterine horn model were analysed by Student's t-test. Statistical analysis of the number of sites that were adhesion-free was conducted using χ 2 -test. P Ͻ 0.05 was considered significant.
Results

Administration of PNU83,836E via Alzet pump Sidewall model
The ability of the non-steroidal lazaroid, PNU83,836E, to reduce adhesion formation in the rabbit sidewall model was tested. Administration at concentrations of 0.06 and 0.6 mg/ ml for 7 days postoperatively to the site of sidewall injury significantly reduced the formation of adhesions to 30.0 Ϯ 14.8% (P ϭ 0.006) and 10.0 Ϯ 6.8% (P ϭ 0.0001), respectively, when compared with controls (citrate buffer alone) (83.3 Ϯ 7.6%).
Double uterine horn model
In initial studies PNU83,836E was administered to the site of injury for 7 days after abrasion and devascularization of both uterine horns. Table I gives the overall adhesion score after administration of PNU83,836E. Administration at either dose resulted in a significant reduction in the overall adhesion score. These non-parametric data were analysed statistically by rank order as described in the method section, and the results are included in Table I . Table II shows the involvement of the horns in adhesions to various organs. As can be seen, administration of PNU83,836E to the site of injury significantly reduced the percentage of horn adhesions to organ sites. The number of sites without adhesions was also increased by administration of PNU83,836E (Figure 1 ). Studies were then conducted to determine whether administration of PNU83,836E at different doses and for different time periods reduced adhesion formation. At various times after initiation of treatment, the pumps were disconnected from the tube to terminate treatment to the injury site. Table III presents the overall adhesion score after administration of PNU83,836E for 1, 2 or 3 days. Administration of both doses at all time points resulted in a significant reduction in the overall adhesion score. However, there was a greater reduction after 72 h than after 24 h. Table IV shows the involvement of the horns in adhesions to various organs. Administration of PNU83,836E to the site of injury significantly reduced the percentage of horn adhesions to other organs. The number of sites without adhesions was also increased by PNU83,836E administration ( Figure 2 ).
Administration of lazaroids in a bolus at the end of surgery Sidewall model
The effect of administration of formulations containing either PNU83,836E or PNU74006F in a volume of 5 ml (1 mg/ml) at the end of surgery can be seen in Figure 3 . The area of the 2446 sidewall injury involved in adhesion formation was significantly (P Ͻ 0.05) reduced after administration of all three formulations when compared with their vehicle controls. Double uterine horn model The efficacy of the same formulations when administered at the end of surgery was also analysed in the rabbit double uterine horn model. The overall score given to the rabbits and the rank order analysis of these data are shown in Table V . The extent of adhesion formation at the individual organ sites and the number of the sites which were adhesion-free can be seen in Table VI and Figure 4 , respectively. Administration of both steroidal and non-steroidal lazaroids at the end of surgery significantly reduced adhesion formation in this model.
Administration of a bolus of PNU74006F before and after surgery
As lazaroids may act to limit adhesion formation by reducing the injury to the tissue resulting from surgical trauma, the effect of pretreatment with PNU74006F at the site of injury before surgery was examined. PNU74006F was administered via i.p. injection 10 min before surgery with (pre/post) or without (pre) subsequent treatment at the conclusion of surgery. The results of this study can be seen in Tables VII (overall score and rank order analysis) and VIII (the percentage of the horns involved in adhesions to various organs) as well as Figure Results are expressed as % organ involvement in uterine horn adhesion. a P ഛ 0.05 compared with controls. 17.5 Ϯ 0.0 a 15.5 Ϯ 2.7 a 33.5 Ϯ 1.3 13.2 Ϯ 7.9 b 10.9 Ϯ 3.9 a a P Ͻ 0.001 compared with control. b P ϭ 0.026 compared with control.
5 (the percentage of sites without adhesions). Administration of different concentrations of PNU74006F either before or before and after surgery reduced adhesion formation in this rabbit model. All formulations and treatment methods tested reduced adhesion formation compared with placebo-treated controls. Further, these effects were dose-dependent and the benefit was increased if treatment was both before and at the end of surgery.
Dose-response study
To conduct a dose-response study, different doses of lazaroid were administered at the beginning and end of surgery in different volumes (2.5 ml at the beginning; 15 ml at the end 2447 of surgery). The results of this study can be seen in Figure 6 (rank order analysis of overall adhesion score) and Table IX (the percentage of horns involved in adhesion to various organs) as well as Figure 7 (the percentage of sites without adhesions). Maximal efficacy was observed in rabbits that received a total of 3 mg of lazaroid. No effect was observed after administration of 0.3 mg of lazaroid.
Adhesion reformation study
The effect of administration of lazaroid (50 mg/rabbit total; 25 mg pre-and postoperatively) on the reformation of lysed adhesions was evaluated. Both the extent (Figure 8 ) and Figure 3 . The percentage of the area of the sidewall injury involved in adhesion formation following administration of a single lazaroid bolus in three different formulations. The area was reduced (P ഛ 0.05 indicated by *) in all lazaroid-exposed rabbits compared with their vehicle controls. Results are expressed as the mean and SE of data from seven rabbits per group. incidence (0/10 control rabbits adhesion-free; 5/10 lazaroid rabbits adhesion-free, P ϭ 0.039) of adhesion reformation were significantly reduced.
Discussion
In this study, the effect of two lazaroids, PNU83,836E (a nonsteroidal compound) and PNU74006F (a steroidal compound), on the formation of i.p. adhesions was studied. PNU83,836E was shown to significantly reduce adhesion formation in two animal models. Administration of the compound for as little as 24 h reduced the formation of adhesions although administration for longer periods of time further increased the efficacy of the compound. Further, administration of lazaroids in various formulations at the end of surgery was also efficacious in the reduction of adhesion formation. Pretreatment with the steroidal lazaroid, PNU74006F, prior to the initiation of surgery followed by a bolus at the conclusion of surgery was the most effective method of reducing adhesion formation. This indicates that the administration of compounds that will reduce inflammation and lipid peroxidation during the first 3 days after surgery can reduce the formation of peritoneal adhesions. Because of its Figure 6 . The rank order analysis of the overall adhesion score is shown following administration of different doses of lazaroid before and after surgery. The bar described as 50 mg (old) represents a group in which the medicament was given in a manner comparable to Tables VII and VIII and Figure 5 , i.e. 5 ml volume before and after surgery. Results are expressed as mean Ϯ SEM from nine or 10 rabbits per group. *P ഛ 0.05 compared with control. lipophilicity (calculated log partition ϭ 8), PNU74006F is likely to be deposited into lipid and released slowly from the site of administration. This hypothesis is supported by several pharmacokinetic studies which show a prolonged beta halflife (of the order of 60-120 h) for this compound after administration via a variety of routes. This characteristic of the compound would allow the abdominal tissues (e.g. omentum and other fat deposits) to act as a slow release depot in a manner analogous to the miniosmotic pumps over the early (5 days) postoperative interval. The steroid lazaroids were developed as antioxidant steroids to reduce inflammation without the immunosuppressive effects or modulation of pituitary function which occur with the administration of glucocorticoids. The initial series of 21aminosteroids (e.g. PNU74006F) were shown to be effective in the reduction of secondary tissue damage in several traumatic and ischemic injury models, particularly models of central nervous system disease (Braughler and Hall, 1989; Choi and Ehrlich, 1993; Aoki and Lefer, 1996) . The protective effects of lazaroids from this series have been attributed to their ability to inhibit lipid peroxidation reactions as well as to lead to the production of reactive oxygen metabolites (e.g. hydrogen peroxide and free radicals) by leukocytes and monocytes (Braughler et al., 1987; Braughler and Pregenzer, 1989; Fisher et al., 1990 Fisher et al., , 1991 Shappell et al., 1994) . In the second generation of lazaroids the steroid modality of the molecule was substituted with a methylaminochroman, resulting in a series of non-steroidal lazaroid compounds (e.g. PNU83,836E) (Hall, 1992) . These compounds were selected for their ability to inhibit lipid peroxidation.
In this study, one compound from each generation of lazaroids was shown to reduce adhesion formation, presumably through the reduction of lipid peroxidation and tissue damage secondary to trauma and ischaemia. Studies have shown that trauma and ischaemia reduce the fibrinolytic activity of parietal peritoneum (Buckman et al., 1976) . Peritoneal fibrinolytic activity was shown to decrease immediately and to continue to decrease 24 h after three different types of trauma (excision, grafting and ischaemia) (Raftery, 1981) . This suggests that secondary damage occurs after these acute injuries which further reduces fibrinolytic activity. As lazaroids reduce secondary damage that occurs after acute trauma and ischaemia, it is conceivable that they act to ameliorate the inhibition of fibrinolysis that occurs in our surgical model. Hence, the deposited fibrin would be more rapidly cleared, thereby reducing the amount of fibrin available for adhesion formation. This will be investigated in future studies.
In summary, a steroidal lazaroid, PNU74006F, and nonsteroidal lazaroid, PNU83,836E, were shown to reduce adhesion formation after surgical trauma and adhesion reformation after adhesiolysis in three rabbit models when delivered to the site of injury. The optimal treatment regimen was shown to be administration of PNU74006F, diluted from a cosolvent system into crystalloid, before the initiation of surgery and at the end of surgical trauma.
